NEW YORK – MedMira announced on Tuesday that its RevealCOVID-19 Plus Total Antibody Test has received CE marking and will be available in countries accepting the designation.
The test detects the presence of total antibodies against SARS-CoV-2 generated by either a previous infection or after vaccination. Results can be achieved within three minutes from the time of the blood draw, and the test is intended for use in doctors' offices, pharmacies, or for large-scale screening programs. The test is available in single packs for individual use or bulk packages for larger scale testing, the company said in a statement.
"We believe the RevealCOVID-19 Plus is our next step in Europe to support the health care system by allowing a more personalized responsibility approach by offering an easy testing tool and the quickest possible time," MedMira CEO Hermes Chan said in a statement.
Halifax, Nova Scotia-based MedMira has three other COVID-19 products, including another antibody test, the RevealCOVID-19 Nab-Y, that it plans to launch in the next few weeks in Europe that will complement the RevealCOVID-19 test. It also has tests for other infectious diseases, including HIV and syphilis, using its rapid vertical flow technology.
In May 2020, the firm announced that Webb Diagnostic Technologies would distribute its RevealCOVID-19 Total Antibody test.